Orforglipron

What is Orforglipron?

Orforglipron is a new treatment for weight management. Orforglipron is a GLP-1 receptor agonist. This means it works in the same way as Wegovy and Mounjaro. Unlike those treatments, which are given as weekly injections, Orforglipron is taken as a daily pill.

These types of medicines were first developed to treat type 2 diabetes. Clinical trials then revealed that they also help people lose weight.

Orforglipron belongs to a new class of small-molecule, non-peptide medicines. Because of this, your body can break it down and absorb it properly when you take it by mouth.

Previous versions of oral GLP-1 treatments were too complicated for this method. Orforglipron is easier to use and offers better absorption, making it a simpler and more effective option.

Eli Lilly has now opted to give orforglipron the brand name Foundayo.

How Does Orforglipron Work?

Orforglipron is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by binding to your body’s GLP-1 receptors. These receptors are normally used to control your hunger.

When they are activated, they make you feel full. They also slow digestion to allow more to be drawn from the food you eat.

While this was originally designed to help people with type-2 diabetes, they had obvious applications for weight loss. In combination with a healthy diet and exercise, Orforglipron can make it easier for you to lose weight.

Orforglipron has a non-peptide structure. This allows it to be taken by mouth without losing effectiveness

Research has shown that Orforglipron keeps a high level of affinity even at lower receptor occupancy. This helps to minimize the risk of adverse outcomes while still providing an effective treatment outcome.

What are Orforglipron’s Side Effects?

As Orforglipron has not been licensed in the UK, we do not have a full list of side effects. As a GLP-1 medication, it is safe to assume it may cause gastrointestinal side effects, including;

• Nausea
• Vomiting
• Diarrhoea
• Abdominal discomfort

These effects may be felt most at the start of your treatment. They should improve as your body gets used to the medication. Clinical trials have shown that Orforglipron is roughly as safe as other GLP-1 medications.

Please note that these are possible side effects; we will have a full list once Orforglipron has been licensed in the UK.

In rare cases, patients may have more serious effects. We advise them to talk to their doctor or get urgent help if they are worried about these effects.

How to Take Orforglipron?

As an oral pill, we expect Orforglipron to be taken once a day with or without food. As Orforglipron has not yet been licensed in the UK, we cannot say for sure what the dosing schedule will be. The dose may vary depending on whether it is being used to treat type 2 diabetes or obesity.

If you are using Orforglipron for weight loss, it is important to add exercise and change your diet. You may find Orforglipron to be less effective than it could be without these changes.

How to Store Orforglipron

Orforglipron should be stored in its original packaging at room temperature. This should be between 20°C and 25°C (68°F to 77°F).

Keep away from direct sunlight, moisture, and heat. Store out of reach of children and pets.

Contraindications and Interactions of Orforglipron

Do not take Orforglipron if you;

• Are allergic to Orforglipron or any of the other ingredients
• Are allergic to any other GLP-1 medications
• Have a history of gastrointestinal problems

This treatment may interact with medications that reduce blood sugar levels, including;

• Insulin
• Sulfonylureas

These interactions could increase the risk of low blood sugar (hypoglycemia).

Patients should tell their healthcare provider about all medications, supplements, and herbal remedies they are using. This helps avoid possible negative interactions.

This list is not exhaustive. Further interactions may emerge through the clinical trials. For more information about who is safe to take Orforglipron, please consult the Patient Information Leaflet.

When will Orforglipron be Available in the UK?

The manufacturer of Foundayo, Eli Lilly, expects that the medication will be approved and available by early 2026.

Regulatory reviews and other issues may create delays.

As such, we cannot guarantee Orforglipron’s UK release date. We also cannot guarantee Orforglipron’s price until then.

Points of Interest (So Far) in Orforglipron Phase 3 Trials

1. Weight Loss Efficacy: Orforglipron has shown weight loss results comparable to those achieved with injectable GLP-1 receptor agonists.
2. Cardiovascular Benefits: Studies report significant reductions in inflammatory and cardiovascular markers, suggesting added health benefits beyond weight loss.
3. Convenience: Taking medicine by mouth is much easier than getting injections. This helps patients stick to their treatment.
4. Long-Term Safety: Ongoing studies aim to establish Orforglipron’s safety and tolerability over extended periods.

Orforglipron (Foundayo) Summary

Alternatives

Some patients may find that Orforglipron isn’t effective for them. We have a number of alternatives available;

• Wegovy (GLP-1 medication)
• Mounjaro (GLP-1 and GIP medication)
• Orlistat (fat-binding pill)

References

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron, Science Translational Medicine, 16(778).

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesitym The New England Journal of Medicine.

Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis, Obesity science & practice.

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA), clinical trials.gov

Author

	Name	Ian Coakley
	Role	Content Writer
	Qual.	Dipl. Biology (Immunology)
	About	Ian joined Simple Online Pharmacy in 2021, and became their first Content Writer in 2022. He uses his experience as a writer and freelance editor to ensure Simple Online Pharmacy has a high quality of content, and aims to provide patients with the right information to make educated decisions about their healthcare.